Semaglutide vs Liraglutide: What the Research Compares

Semaglutide and liraglutide are two prescription glucagon-like peptide-1 (GLP-1) receptor agonists developed by the same research programme. They share a receptor target and a general pharmacological class, but differ in how their molecules were engineered, how often they are administered, and how much and what kind of outcome data has accumulated for each. This page summarises what published trials and reviews reported when the two were compared, directly and indirectly.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or any prescription medicine. Nothing here describes how either drug should be used. Both are prescription medicines, and every question about suitability, dosing, monitoring or interactions belongs with a prescribing clinician.

Same class, different molecules

Both compounds are analogues of the human incretin hormone GLP-1, modified so they resist rapid enzymatic breakdown and bind albumin in circulation. A historical review of the discovery programme behind both molecules described liraglutide as an acylated GLP-1 analogue developed for once-daily administration, and semaglutide as a later molecule carrying further structural modifications that extended its half-life enough to support once-weekly administration (PMID 31031702). The medicinal chemistry paper describing semaglutide's discovery reported that the design combined substitution at position 8 to reduce DPP-4 degradation with a modified fatty di-acid side chain and spacer that increased albumin affinity, producing the longer exposure profile that distinguished it from liraglutide (PMID 26308095).

A state-of-the-art review of GLP-1 receptor agonists in type 2 diabetes placed both drugs within the same therapeutic class, describing shared mechanisms including glucose-dependent stimulation of insulin secretion, suppression of glucagon release, slowing of gastric emptying and central effects on appetite (PMID 33068776). The practical difference researchers emphasised was pharmacokinetic rather than mechanistic: the same receptor, engaged with different duration of exposure.

Administration interval and formulation

Liraglutide has been studied as a once-daily subcutaneous injection; semaglutide has been studied as both a once-weekly subcutaneous injection and an oral tablet. A review of semaglutide formulations reported that an oral version was developed using an absorption enhancer to permit gastrointestinal uptake of the peptide, and compared the efficacy profiles of the subcutaneous and oral routes (PMID 34248838). No comparable oral liraglutide product featured in that review. This page does not state doses for either medicine; dosing is a prescribing decision.

Head-to-head trials: what the direct comparisons measured

Unlike many peptide comparisons, this one has published randomised head-to-head data in adults with obesity.

STEP 8

The STEP 8 randomised clinical trial compared once-weekly subcutaneous semaglutide with once-daily liraglutide in adults with overweight or obesity without diabetes, with placebo arms, and reported that semaglutide produced significantly greater mean body weight reduction than liraglutide over the 68-week treatment period (PMID 35015037). The trial was published in JAMA in 2022 and was designed specifically as an active-comparator study rather than an indirect comparison (PMID 35015037).

The phase 2 dose-ranging trial

An earlier randomised, double-blind, placebo- and active-controlled, dose-ranging phase 2 trial in patients with obesity compared semaglutide against both liraglutide and placebo, and reported greater weight loss with semaglutide than with placebo across the dose range studied, alongside safety data for both active comparators (PMID 30122305). That trial, published in the Lancet in 2018, is the other principal direct comparison in the obesity literature (PMID 30122305).

Both head-to-head trials were conducted in populations with overweight or obesity. Readers should note what the trials did not do: neither was designed as a head-to-head cardiovascular outcomes trial, and the direct comparative evidence outside weight endpoints is thinner than the within-drug evidence base for each molecule separately.

Side-by-side: what the literature covers for each

Regulatory status

Both are prescription medicines, and both appear in clinical reviews as approved pharmacotherapies. A 2024 JAMA review of medications for obesity described the approved drug options available to clinicians treating obesity and discussed GLP-1 receptor agonists among them (PMID 39037780). A 2024 review of weight loss pharmacotherapy similarly surveyed current and emerging agents and their place in clinical practice (PMID 39277293). Specific approved indications, labelling and availability differ by country and change over time; a prescribing clinician or the current product labelling is the accurate source for any individual case.

The trials summarised here studied supervised administration of licensed or investigational product under protocol.

Adverse Events: What Studies Report

Gastrointestinal effects dominate the reported adverse-event profile for this drug class. A 2023 JAMA research letter examining the risk of gastrointestinal adverse events associated with GLP-1 receptor agonists used for weight loss reported increased risks of events including pancreatitis, gastroparesis and bowel obstruction compared with a non-GLP-1 weight loss agent (PMID 37796527). A review written for emergency clinicians summarised the adverse effects of GLP-1 agonists most likely to present acutely, including gastrointestinal symptoms and considerations relevant to urgent care settings (PMID 38241775).

In the direct comparison, STEP 8 reported gastrointestinal adverse events in both the semaglutide and liraglutide arms, with discontinuation data presented for each group (PMID 35015037). The phase 2 dose-ranging trial likewise reported safety outcomes for semaglutide alongside liraglutide and placebo (PMID 30122305).

On a frequently raised question, a 2023 systematic review and meta-analysis examined semaglutide and cancer outcomes and reported on the available trial data addressing that signal (PMID 37531876). A 2025 systematic review and meta-analysis of pharmacological treatments for obesity in adults pooled efficacy and safety data across agents, providing a class-level view of how adverse events were distributed across available drugs (PMID 41039116). Individual risk is not something a meta-analysis can determine for a particular person; that assessment belongs with a clinician who knows the patient's history.

How to read a comparison like this

Several limitations matter when interpreting semaglutide-versus-liraglutide data:

• Dose selection drives comparisons. Active-comparator trials compare specific doses of each drug, not the drugs in the abstract. The phase 2 trial was explicitly a dose-ranging study, meaning several semaglutide doses were tested against a single comparator design (PMID 30122305).
• Population matters. STEP 8 enrolled adults with overweight or obesity without diabetes, so its findings describe that population rather than people with type 2 diabetes (PMID 35015037).
• Endpoint matters. Mean percentage weight change, glycaemic control, cardiovascular outcomes and tolerability are separate endpoints; a result on one does not transfer to another, as the breadth of outcomes covered in class reviews illustrates (PMID 33068776).
• Meta-analyses pool heterogeneous trials. The 2025 obesity pharmacotherapy meta-analysis combined studies of different agents, durations and populations, and such pooling carries its own uncertainty (PMID 41039116).
• Tolerability is individual. Group-level adverse event rates, such as the gastrointestinal risks reported in the 2023 JAMA analysis, describe populations rather than predicting any individual's experience (PMID 37796527).

What the comparison does not establish

A trial showing a larger average effect on one endpoint does not identify a "better" medicine for any given person. Clinical reviews of obesity pharmacotherapy described selection as depending on comorbidities, tolerability, contraindications, access and patient preference rather than on a single efficacy ranking (PMID 39037780), and a 2024 review of current and future weight loss therapies framed the expanding drug landscape in similar terms (PMID 39277293). This page therefore reports what the studies measured and declines to name a preferred option. That judgement is a clinical one.

For deeper background on each molecule separately, see the PeptideU learn pages on semaglutide and liraglutide, which summarise the individual evidence bases in more detail.

References

• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial (JAMA, 2022)
• Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial (Lancet, 2018)
• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Journal of Medicinal Chemistry, 2015)
• GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art (Molecular Metabolism, 2021)
• Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation (Frontiers in Endocrinology, 2021)
• Medications for Obesity: A Review (JAMA, 2024)
• Weight Loss Pharmacotherapy: Current and Future Therapies (Gastrointestinal Endoscopy Clinics of North America, 2024)
• A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (Nature Medicine, 2025)
• Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (JAMA, 2023)
• GLP-1 agonists: A review for emergency clinicians (American Journal of Emergency Medicine, 2024)
• Semaglutide and cancer: A systematic review and meta-analysis (Diabetes & Metabolic Syndrome, 2023)